Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-8.97%
-4.37%
-0.07%
+1.66%
+5.77%
Most Trending
-8.97%
-4.37%
-0.07%
+1.66%
+5.77%
Moderna fell by 16% in trading on the Nasdaq last week. In doing so, the company completed a drop of about 70% from the record it recorded during the year 2021, and in fact almost returned to its level before the outbreak of the corona epidemic in the Western world at the beginning of 2020.
Moderna is an American pharmaceutical and biotechnology company focused on drug development using mRNA technology. It was one of the first companies to receive approval from the US Food and Drug Administration (FDA) to distribute the vaccine against the corona virus, in December 2020.
The presumed reason for the sharp drop in the stock value is that the company currently has a marketing approval for only one product, the Spikevax corona vaccine. Although the company emphasized that there are several drugs in development (such as a flu vaccine and a more advanced corona vaccine), these have not yet been approved by the FDA in advanced stages.
At the same time, the company stated that it expects sales of only $5 billion dollars this year, most of them in the second half of the year, against the analysts' estimates of about $7.9 billion.
Please note that the article should not be considered as investment advice or marketing, and it does not take into account the personal data and requirements of any individual. It is not a substitute for the reader's own judgment, and it should not be considered as advice or recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
Receive our Daily Alerts
Enter your email to receive daily alerts
Leading Gainers
Upgrades
Downgrades
Top Leaders
Ipo's
Dividend
Option Activity
Insiders Activity
Institutional Holdings
New Products
FDA Approvals
Agreements
Financial Reports
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
FIND US ON
Receive our Daily Alerts
Enter your email to receive daily alerts
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.